Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05604105 | Oral Cancer Awareness in Egypt | not yet recruiting | — | 1,844 | Ayat Gamal-AbdelNaserOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT06093425 | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma | not yet recruiting | Phase 3 | 820 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT06991738 | 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer | not yet recruiting | Phase 1 / Phase 2 | 18 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07005297 | Clinical Genetics Branch Eligibility Screening Survey | not yet recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07219199 | Residual IDH1-Mutant Tumor Cell Quantification Study | not yet recruiting | N/A | 105 | NYU Langone HealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07349134 | WELL-MPN: A Digital Lifestyle App for Patients With MPNs(WELL-MPN) | not yet recruiting | N/A | 75 | Brigham and Women's HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07361484 | Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) | not yet recruiting | Phase 3 | 442 | BeyondSpring Pharmaceuticals Inc.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07472322 | ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 | not yet recruiting | Phase 1 / Phase 2 | 31 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | not yet recruiting | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07574541 | Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance | not yet recruiting | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07597070 | Universal Immunization to Fortify Immunotherapy Efficacy and Response(UNIFIER) | not yet recruiting | Phase 2 | 500 | University of FloridaOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07706179 | Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer | not yet recruiting | Phase 2 | 10 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | not yet recruiting | Phase 1 / Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | not yet recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07756840 | Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) | not yet recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07766187 | Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma(CODAH) | not yet recruiting | Phase 2 | 12 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor | not yet recruiting | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07823907 | Ultrasound-Guided Microwave Ablation for Breast Fibroadenoma: Safety and Cosmetic Outcomes(MWA-FA) | not yet recruiting | N/A | 40 | Al-Azhar UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845669 | Effects of Synbiotic Supplementation on Gastrointestinal Symptoms, Appetite, and Nutritional Recovery in Patients After Autologous Bone Marrow Transplant | not yet recruiting | N/A | 40 | Alexandria UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845786 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLAR-202) | not yet recruiting | Phase 2 | 60 | ExelixisINDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07845877 | An Intervention to Reduce Sedentary Behavior and Promote Physical Activity in Colorectal Cancer Chemotherapy | not yet recruiting | N/A | 40 | Yonsei UniversityOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07845916 | Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer(QS-NSCLC) | not yet recruiting | Phase 2 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845994 | SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years(SEMAFORCRANIO) | not yet recruiting | Phase 3 | 50 | University Hospital, AngersOTHER_GOV | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846046 | Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer(ENSURE) | not yet recruiting | N/A | 246 | Amsterdam UMC, location VUmcOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846267 | Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma(CASTLE-ZS-05) | not yet recruiting | Phase 2 | 56 | Fudan UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846358 | This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.(GFH276X1203) | not yet recruiting | Phase 1 / Phase 2 | 84 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07846592 | Real-time Fluorescence Microscopy for Intraoperative Assessment of Prostate Biopsy Cores (FLASH)(FLASH) | not yet recruiting | — | 450 | Shanghai East HospitalOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07847060 | Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma | not yet recruiting | N/A | 60 | Assiut UniversityOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07847216 | Multicenter Prospective Study Protocol for Validating Surgical Quality Standards in D3 Lymphadenectomy for Oncological Right Hemicolectomy(D3L) | not yet recruiting | — | 120 | Fundació d'investigació Sanitària de les Illes BalearsOTHER_GOV | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07847398 | Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.(EMMENEO-TN) | not yet recruiting | N/A | 50 | Centre Antoine LacassagneOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847671 | Fecal Microbiota Transplantation With QL1706 Plus Bevacizumab for Advanced HCC | not yet recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847957 | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL | not yet recruiting | Phase 1 / Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07848061 | A Master Regulator of Lipid-Associated Macrophage Function in Cancer(FoMe-LAM) | not yet recruiting | — | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07515651 | Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity(MIDAS-SBRT) | not yet recruiting | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07578649 | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer | not yet recruiting | Phase 3 | 600 | PfizerINDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07691762 | A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 690 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | not yet recruiting | Phase 1 / Phase 2 | 60 | University Health Network, TorontoOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07737314 | Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study | not yet recruiting | N/A | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07740317 | Neurocognitive Trajectories After BCMA CAR-T(CAR-T Cog) | not yet recruiting | — | 50 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07836933 | Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL) | not yet recruiting | N/A | 50 | University of California, San FranciscoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07842679 | Cognitive Impairment in Older Adults With Hematologic Malignancies | not yet recruiting | — | 120 | Assiut UniversityOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07843303 | Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II,Multicenter, Single-Arm Study | not yet recruiting | Phase 2 | 53 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843537 | MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study | not yet recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843641 | A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST) | not yet recruiting | Phase 2 | 72 | GlaxoSmithKlineINDUSTRY | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07844018 | ADC Based Therapy Accroding to HER2 Heterogeneous(HER2level) | not yet recruiting | Phase 2 | 88 | Peking University People's HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844057 | First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma(FIRE-12) | not yet recruiting | Phase 2 | 86 | Annika KurreckOTHER | 1 | Sep 28, 2026 | clinicaltrials |
Data updated 15 hours agoSource updated Sep 29, 2026source: clinicaltrials